Side-by-side evidence map
| Question | Retatrutide | Cagrilintide |
|---|---|---|
| Mechanism | GLP-1, GIP, and glucagon agonism | Long-acting amylin analog |
| Development context | Studied as a single triple agonist | Often studied with semaglutide as CagriSema |
| Regulatory status | Investigational | Investigational |
| Direct comparison | No head-to-head trial | No head-to-head trial |
How to read the numbers
A larger percentage reported in one trial does not prove superiority over a result from another trial. A valid treatment comparison requires a head-to-head design or a carefully specified indirect analysis.
What this evidence review covers
Compare two investigational programs with different mechanisms while making the no-head-to-head/no-demand-data limitation prominent.
- Mechanism and status
- Retatrutide phase 2 evidence
- Cagrilintide phase 2 evidence
- Different populations/durations/estimands
- Cagrilintide is not CagriSema
- No stack or combination instructions
Source-backed findings
Each claim below is tied to the evidence class that can support it. Commercial listing data and clinical evidence remain separate.
separate trial facts
Cagrilintide's cited phase 2 trial was a 26-week dose-finding study; Retatrutide's cited obesity phase 2 trial ran 48 weeks.
regulatory
FDA states neither Retatrutide nor cagrilintide has been found safe and effective, and neither can be used in compounding under federal law.
| Evidence class | What the source supports |
|---|---|
| separate trial facts | Cagrilintide's cited phase 2 trial was a 26-week dose-finding study; Retatrutide's cited obesity phase 2 trial ran 48 weeks. |
| regulatory | FDA states neither Retatrutide nor cagrilintide has been found safe and effective, and neither can be used in compounding under federal law. |
Source-by-source evidence notes
These notes state what each inspected source can support and the boundary that should not be crossed when interpreting it.
Once-weekly cagrilintide phase 2 dose-finding trial
Evidence class: primary randomized phase 2. What it supports: Dose-finding design, n=706 cagrilintide participants plus controls, 26-week weight outcomes, and adverse events.
What it does not establish: A direct comparison with retatrutide, CagriSema claims, or a combination/stack protocol.
Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial
Evidence class: primary randomized phase 2. What it supports: n=338 obesity/overweight trial; receptor description; dose arms; 24- and 48-week weight outcomes; reported adverse events.
What it does not establish: Approved use, long-term benefit-risk, vendor-product equivalence, cross-trial superiority, or a consumer protocol.
FDA concerns with unapproved GLP-1 drugs used for weight loss
Evidence class: primary regulatory. What it supports: Retatrutide and cagrilintide are not components of approved drugs, have not been found safe and effective, and cannot be used in compounding under federal law; FDA warnings about false research labels.
What it does not establish: A general claim that every observed listing is unlawful in every jurisdiction.
Questions this page answers
Which is better?
No direct comparison was identified. Present separate evidence and avoid a winner.
Can they be used together?
The packet does not support a combination protocol; do not infer one from separate monotherapy trials or CagriSema studies.
What remains unresolved
- Manifest recorded zero query-evidence rows for this route; demand is unsupported/unknown.
- No head-to-head trial.
- No Retatrutide+cagrilintide combination evidence packet.
- Consider noindex/hold until the owner confirms demand and editorial value.